252 related articles for article (PubMed ID: 27666548)
21. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.
Bi H; Yin L; Fang W; Song S; Wu S; Shen J
Lab Med; 2023 Jul; 54(4):372-379. PubMed ID: 36282321
[TBL] [Abstract][Full Text] [Related]
22. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
23. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
Li L; Zhang Q; Wang Y; Xu C
J Clin Lab Anal; 2023 Apr; 37(7):e24865. PubMed ID: 37088873
[TBL] [Abstract][Full Text] [Related]
24. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract][Full Text] [Related]
25. The predictive value of delta-like3 and serum NSE in evaluating chemotherapy response and prognosis in patients with advanced small cell lung carcinoma: An observational study.
Zhu C; Huang J; Jin X; Zhang C; Zhu C; Lv M; Chen S; Du X; Feng G
Medicine (Baltimore); 2024 Jun; 103(23):e38487. PubMed ID: 38847733
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
Muley T; Herth FJ; Heussel CP; Kriegsmann M; Thomas M; Meister M; Schneider MA; Wehnl B; Mang A; Holdenrieder S
Tumour Biol; 2024; 46(s1):S219-S232. PubMed ID: 37840518
[TBL] [Abstract][Full Text] [Related]
27. Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).
Jørgensen LG; Osterlind K; Hansen HH; Cooper EH
Br J Cancer; 1994 Oct; 70(4):759-61. PubMed ID: 7917935
[TBL] [Abstract][Full Text] [Related]
28. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].
WANG J; GAO J; HE J
Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1094-100. PubMed ID: 21159242
[TBL] [Abstract][Full Text] [Related]
29. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
30. Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS.
Torsetnes SB; Levernæs MS; Broughton MN; Paus E; Halvorsen TG; Reubsaet L
Anal Chem; 2014 Jul; 86(14):6983-92. PubMed ID: 24945626
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer.
Lim SC; Park KO; Kim YC; Na KJ; Song H; Bom HS
Cancer Biother Radiopharm; 2000 Aug; 15(4):381-6. PubMed ID: 11041023
[TBL] [Abstract][Full Text] [Related]
32. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer.
Kim HR; Oh IJ; Shin MG; Park JS; Choi HJ; Ban HJ; Kim KS; Kim YC; Shin JH; Ryang DW; Suh SP
J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852
[TBL] [Abstract][Full Text] [Related]
33. A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test.
Muley T; Zhang X; Holdenrieder S; Korse CM; Zhi XY; Molina R; Liu Z; Hartmann G; van den Heuvel MM; Qian K; Marrades R; Engel C; He Y; Wehnl B; Dayyani F; Herth F
Tumour Biol; 2020 Sep; 42(9):1010428320958603. PubMed ID: 32964798
[TBL] [Abstract][Full Text] [Related]
34. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
35. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
36. IL-6 and VEGF in small cell lung cancer patients.
Wójcik E; Jakubowicz J; Skotnicki P; Sas-Korczyńska B; Kulpa JK
Anticancer Res; 2010 May; 30(5):1773-8. PubMed ID: 20592377
[TBL] [Abstract][Full Text] [Related]
37. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
Takada M; Kusunoki Y; Masuda N; Matui K; Yana T; Ushijima S; Iida K; Tamura K; Komiya T; Kawase I; Kikui N; Morino H; Fukuoka M
Br J Cancer; 1996 May; 73(10):1227-32. PubMed ID: 8630283
[TBL] [Abstract][Full Text] [Related]
38. Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.
Li L; Zhang Z; Hu Y
Medicine (Baltimore); 2021 Sep; 100(36):e27029. PubMed ID: 34516493
[TBL] [Abstract][Full Text] [Related]
39. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer.
Pinson P; Joos G; Watripont P; Brusselle G; Pauwels R
Respiration; 1997; 64(1):102-7. PubMed ID: 9044484
[TBL] [Abstract][Full Text] [Related]
40. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]